1. Academic Validation
  2. MG53-IRS-1 (Mitsugumin 53-Insulin Receptor Substrate-1) Interaction Disruptor Sensitizes Insulin Signaling in Skeletal Muscle

MG53-IRS-1 (Mitsugumin 53-Insulin Receptor Substrate-1) Interaction Disruptor Sensitizes Insulin Signaling in Skeletal Muscle

  • J Biol Chem. 2016 Dec 23;291(52):26627-26635. doi: 10.1074/jbc.M116.754424.
Hyun Lee 1 Jung-Jin Park 1 Nga Nguyen 1 Jun Sub Park 1 Jin Hong 1 Seung-Hyeob Kim 1 Woon Young Song 2 Hak Joong Kim 2 Kwangman Choi 3 Sungchan Cho 3 Jae-Seon Lee 4 Bong-Woo Kim 5 Young-Gyu Ko 6
Affiliations

Affiliations

  • 1 From the Division of Life Sciences and.
  • 2 the Department of Chemistry, Korea University, Seoul, 02841, Korea.
  • 3 the Targeted Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Korea, and.
  • 4 the Department of Biomedical Sciences, College of Medicine, Inha University, Incheon, 22212, Korea.
  • 5 From the Division of Life Sciences and [email protected].
  • 6 From the Division of Life Sciences and [email protected].
Abstract

Mitsugumin 53 (MG53) is an E3 ligase that interacts with and ubiquitinates Insulin Receptor substrate-1 (IRS-1) in skeletal muscle; thus, an MG53-IRS-1 interaction disruptor (MID), which potentially sensitizes Insulin signaling with an elevated level of IRS-1 in skeletal muscle, is an excellent candidate for treating Insulin resistance. To screen for an MID, we developed a bimolecular luminescence complementation system using an N-terminal luciferase fragment fused with IRS-1 and a C-terminal luciferase fragment fused with an MG53 C14A mutant that binds to IRS-1 but does not have E3 ligase activity. An MID, which was discovered using the bimolecular luminescence complementation system, disrupted the molecular association of MG53 with IRS-1, thus abolishing MG53-mediated IRS-1 ubiquitination and degradation. Thus, the MID sensitized Insulin signaling and increased insulin-elicited glucose uptake with an elevated level of IRS-1 in C2C12 myotubes. These data indicate that this MID holds promise as a drug candidate for treating Insulin resistance.

Keywords

diabetes; drug discovery; insulin receptor substrate 1 (IRS-1); insulin resistance; skeletal muscle.

Figures
Products